|
|
Study on the expression of bax and bcl-2 in kidney of rats with contrast-induced nephropathy and the intervention of Calcium Dobesilate |
LI Wei1,2 YU Fenfen3 JI Wenxuan3 HE Xiaoyan1 PAN Peiqiang1,3 SUN Yan4 Huang Junyan3 |
1.Medical College, Qingdao University, Shandong Province, Qingdao 266021, China;
2.Department of Nephrology, Pingyi County Hospital of Traditional Chinese Medicine in Linyi City, Shandong Province, Pingyi 273300, China;
3.Department of Nephrology, Qingdao Central Hospital, Shandong Province, Qingdao 266042, China;
4.Department of Nephrology, Qingdao Municipal Hospital, Shandong Province, Qingdao 266011, China |
|
|
Abstract Objective To investigate the expression of bax and bcl-2 in kidney of rats with contrast-induced nephropathy (CIN) and the effects of Calcium Dobesilate. Methods Eighty-four rats were divided into sham operation group (group A), model group (group B) and Calcium Dobesilate intervention group (group C) according to random number table, 28 rats in each group. Group A was given saline, group B was injected with INDO, L-NAME and 760 g/L Diatrizoate, while group C was given Calcium Dobesilate for intragastric administration on the basis of group B. After 12, 24, 48, 72 h model establishment, blood urea nitrogen (BUN) and creatinine (Scr) were measured. Nephropathy was observed by HE staining. Renal cell apoptosis was detected by TUNEL. The expression of bax and bcl-2 were detected by immunohistochemistry and Western blot. Results The levels of BUN and Scr in group B and group C were significantly higher than those in group A at 12, 24, 48, 72 h after the establishment of model, while those in group C were significantly lower than those in group B at 12, 24, 48, 72 h after the establishment of model (P < 0.05). Compared with 12 h after modeling, serum BUN and Scr levels in group B and group C were significantly higher at 24, 48, 72 h after modeling (P < 0.05). Compared with 24 h after model establishment, serum Scr level in group B increased significantly at 48 h after model establishment, serum BUN and Scr levels in group C increased significantly at 48 h after model establishment, and serum Scr level in group C decreased significantly at 72 h after model establishment (P < 0.05). Compared with 48 h after modeling, serum BUN and Scr levels in group B and group C were significantly lower at 72 h after modeling (P < 0.05). In group A, the pathological changes were not significant; in group B, extensive tubular epithelial cell vacuolation, partial tubular necrosis and renal interstitial fibrosis appeared 12 h after modeling; in group C, the renal tubular interstitial lesions were significantly improved. There was no significant apoptosis in group A; the apoptosis index in group B was significantly higher than that in group A; the apoptosis index in group C was significantly lower than that in group B, but higher than that in group A (P < 0.05). The expression level of bax in group B was significantly higher than that in group A, bax in group C was significantly lower than that in group B, but higher than that in group A; the expression level of bcl-2 in group B was significantly lower than that in group A, and the expression level of bcl-2 in group C was significantly higher than that in group B, but lower than that in group A (P < 0.05). The relative expression of bax protein in group B was significantly higher than that in group A, and the relative expression of bax protein in group C was significantly lower than that in group B, but higher than that in group A; the relative expression of bcl-2 protein in group B was significantly lower than that in group A, and the relative expression of bcl-2 protein in group C was significantly higher than that in group B, but lower than that in group A (P < 0.05). Conclusion Apoptosis has close relationship with CIN, and Calcium Dobesilate may play a protective role by reducing the expression of bax and increasing the expression of bcl-2.
|
|
|
|
|
[1] 祝黎东,孙媛媛,陈雷,等.前列地尔联合羟苯磺酸钙对CHD合并CRI患者行PCI时发生对比剂肾病的预防作用[J].中国现代医生,2016,54(30):84-86.
[2] 于芬芬,季文萱,单文红,等.羟苯磺酸钙对对比剂肾病大鼠肾的保护作用[J].中国介入心脏病学杂志,2015,23(8):454-458.
[3] 周懿君,邵兴华,李舒,等.羟苯磺酸钙改善糖尿病肾病的微炎症状态和内皮细胞功能[J].中国血液净化,2019, 18(2):98-103.
[4] 马玉苹,吴红赤.慢性肾病患者对比剂肾病的研究进展[J].临床与病理杂志,2017,37(12):2717-2720.
[5] 余福玲,汪义云,谢泓,等.肾素血管紧张素系统阻断剂对冠状动脉介入治疗后对比剂肾病的影响[J].中华高血压杂志,2017,25(12):1163-1168.
[6] 谢娟,张译元,徐永,等.尿富含半胱氨酸蛋白61在对比剂肾病中的早期诊断价值[J].临床肾脏病杂志,2019,19(4):240-244.
[7] 崔雪林,马自东,陈倩,等.血清同型半胱氨酸、胱抑素C水平对冠脉介入术后对比剂肾病预测价值分析[J].中国医药科学,2019,9(5):245-247.
[8] 魏明明,党艳梅,张少青,等.羟苯磺酸钙对慢性肾衰竭模型大鼠细胞外基质的影响[J].中国中西医结合肾病杂志,2015,16(8):677-679.
[9] 吴新华,高凌成,黄玉杰,等.羟苯磺酸钙对2型糖尿病大血管病变的疗效及分泌型卷曲相关蛋白5的影响[J].西北药学杂志,2019(4):551-555.
[10] 林家煜,姜峥嵘,吴丽珍,等.羟苯磺酸钙对糖尿病肾病患者微炎症状态的影响分析[J].中国医药科学,2019,9(3):227-230.
[11] 王洪宇,裴存文,法利,等.羟苯磺酸钙联合中药治疗糖尿病视网膜病变的疗效观察[J].河北医学,2017,23(11):1926-1928.
[12] 瞿正旭.复方血栓通胶囊联合羟苯磺酸钙治疗糖尿病视网膜病变的疗效观察[J].中国现代医生,2018,56(5):30-32.
[13] 金伟平,蒲柳艳.羟苯磺酸钙联合依帕司他治疗单纯型糖尿病视网膜病变的疗效观察[J].中国现代医生,2019, 57(5):19-22.
[14] 林开阳,陈汉川,王孙蓥,等.呋塞米与对比剂肾病的研究进展[J].临床肾脏病杂志,2019,19(5):376-379.
[15] 李秀珍,谭晓,高逸冰,等.血清中性粒细胞明胶酶相关脂质运载蛋白对对比剂肾病的早期预测价值[J].中华老年多器官疾病杂志,2019,18(3):210-213.
[16] 周庆春,滕录霞,周红辉,等.不同浓度的碘对比剂及注射速度加合理水化与对比剂肾病的相关研究[J].现代医用影像学,2019,28(3):495-497.
[17] 冯京全,柏明见,高智勇,等.尿NGAL、KIM-1联合检测早期诊断对比剂肾病的价值研究[J].国际检验医学杂志,2019,40(3):355-358.
[18] 年蔚,郗爱旗,郑茂蔚,等.高原老年患者口服与静脉水化预防增强CT后对比剂肾病的疗效[J].中国老年学杂志,2018,38(20):4969-4972.
[19] 艾民,张思艺,颜昌福,等.急性冠脉综合征合并H型高血压经皮冠状动脉造影术后对比剂肾病的研究[J].实用医学杂志,2019,35(10):1599-1601.
[20] 卢海燕,吕玲春,沈珈谊,等.N氨基末端脑钠肽前体与冠状动脉造影后对比剂肾病相关性研究[J].介入放射学杂志,2018,27(9):817-821.
[21] 边静,杨金容,汤雯.预见性护理联合水化疗法在预防老年血管造影患者并发对比剂肾病中的应用[J].齐鲁护理杂志,2019,25(12):76-78. |
|
|
|